- Home
- ALEC vs LUNG Comparison
ALEC vs LUNG Comparison
Compare ALEC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- LUNG
- Stock Information
- Founded
- ALEC 2013
- LUNG 1995
- Country
- ALEC United States
- LUNG United States
- Employees
- ALEC N/A
- LUNG N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- ALEC Health Care
- LUNG Health Care
- Exchange
- ALEC Nasdaq
- LUNG Nasdaq
- Market Cap
- ALEC 232.6M
- LUNG 251.5M
- IPO Year
- ALEC 2019
- LUNG 2020
- Fundamental
- Price
- ALEC $1.86
- LUNG $6.23
- Analyst Decision
- ALEC Buy
- LUNG Buy
- Analyst Count
- ALEC 6
- LUNG 6
- Target Price
- ALEC $11.75
- LUNG $11.92
- AVG Volume (30 Days)
- ALEC 2.3M
- LUNG 252.9K
- Earning Date
- ALEC 11-06-2024
- LUNG 02-19-2025
- Dividend Yield
- ALEC N/A
- LUNG N/A
- EPS Growth
- ALEC N/A
- LUNG N/A
- EPS
- ALEC N/A
- LUNG N/A
- Revenue
- ALEC $61,508,000.00
- LUNG $79,302,000.00
- Revenue This Year
- ALEC N/A
- LUNG $22.26
- Revenue Next Year
- ALEC $71.71
- LUNG $18.72
- P/E Ratio
- ALEC N/A
- LUNG N/A
- Revenue Growth
- ALEC N/A
- LUNG 22.34
- 52 Week Low
- ALEC $1.73
- LUNG $5.46
- 52 Week High
- ALEC $8.90
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- ALEC 22.54
- LUNG 41.37
- Support Level
- ALEC $1.74
- LUNG $5.72
- Resistance Level
- ALEC $2.50
- LUNG $6.28
- Average True Range (ATR)
- ALEC 0.16
- LUNG 0.40
- MACD
- ALEC 0.03
- LUNG -0.03
- Stochastic Oscillator
- ALEC 2.37
- LUNG 19.85
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.